Trials assessing endogenous oxytocin concentrations, and those assessing the influence of exogenous oxytocin, should therefore optimise sex stratification in order to identify the potentially differential benefits of oxytocin for male and female patients with craniopharyngioma. The gene discussed is OXT; the disease is craniopharyngioma.